133 related articles for article (PubMed ID: 29953894)
1. Clinicopathological and prognostic significance of SHP2 and Hook1 expression in patients with thyroid carcinoma.
Cao J; Huang YQ; Jiao-Sun ; Lan XB; Ge MH
Hum Pathol; 2018 Nov; 81():105-112. PubMed ID: 29953894
[TBL] [Abstract][Full Text] [Related]
2. The clinicopathological and prognostic implications of tyrosine phosphatase SHP2 and ankyrin Hook1 gene expression in non- small cell lung cancer patients treated with gemcitabine plus platinum as first-line chemotherapy.
Yang H; He L; Zhang Y; Li Y; Huang X; Li Y; Lou Y; Wang L
Ann Palliat Med; 2020 Sep; 9(5):2943-2952. PubMed ID: 32819122
[TBL] [Abstract][Full Text] [Related]
3. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
4. The clinical significance of PINX1 expression in papillary thyroid carcinoma.
Kang J; Han K; Kim HJ; Park JH; Kong JS; Park S; Myung JK
Hum Pathol; 2018 Nov; 81():176-183. PubMed ID: 30026037
[TBL] [Abstract][Full Text] [Related]
5. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
[TBL] [Abstract][Full Text] [Related]
6. SHP2 positively regulates TGFβ1-induced epithelial-mesenchymal transition modulated by its novel interacting protein Hook1.
Li S; Wang L; Zhao Q; Liu Y; He L; Xu Q; Sun X; Teng L; Cheng H; Ke Y
J Biol Chem; 2014 Dec; 289(49):34152-60. PubMed ID: 25331952
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D
Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796
[TBL] [Abstract][Full Text] [Related]
8. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
[TBL] [Abstract][Full Text] [Related]
9. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
[TBL] [Abstract][Full Text] [Related]
10. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
11. Changes in total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer during the past 15 years.
James BC; Timsina L; Graham R; Angelos P; Haggstrom DA
Surgery; 2019 Jul; 166(1):41-47. PubMed ID: 30904172
[TBL] [Abstract][Full Text] [Related]
12. Altered expression of estrogen receptor β2 is associated with different biological markers and clinicopathological factors in papillary thyroid cancer.
Dong W; Li J; Zhang H; Huang Y; He L; Wang Z; Shan Z; Teng W
Int J Clin Exp Pathol; 2015; 8(6):7149-56. PubMed ID: 26261608
[TBL] [Abstract][Full Text] [Related]
13. Risk-adapted management of papillary thyroid carcinoma according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low-risk patients?
Ebina A; Sugitani I; Fujimoto Y; Yamada K
Surgery; 2014 Dec; 156(6):1579-88; discussion 1588-9. PubMed ID: 25262223
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Neck Reoperation and Mortality After Initial Total Thyroidectomy for Differentiated Thyroid Cancer.
Semrad TJ; Keegan THM; Semrad A; Brunson A; Farwell DG
Thyroid; 2018 Sep; 28(9):1143-1152. PubMed ID: 29929451
[TBL] [Abstract][Full Text] [Related]
15. Activation of nuclear factor-κB contributes to growth and aggressiveness of papillary thyroid carcinoma.
Pyo JS; Kang G; Kim DH; Chae SW; Park C; Kim K; Do SI; Lee HJ; Kim JH; Sohn JH
Pathol Res Pract; 2013 Apr; 209(4):228-32. PubMed ID: 23528368
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients.
Wang W; Su X; He K; Wang Y; Wang H; Wang H; Zhao Y; Zhao W; Zarnegar R; Fahey TJ; Teng X; Teng L
Cancer; 2016 Jan; 122(2):198-206. PubMed ID: 26506214
[TBL] [Abstract][Full Text] [Related]
17. SHP2 and UGP2 are Biomarkers for Progression and Poor Prognosis of Gallbladder Cancer.
Wang Q; Yang ZL; Zou Q; Yuan Y; Li J; Liang L; Zeng G; Chen S
Cancer Invest; 2016 Jul; 34(6):255-64. PubMed ID: 27389087
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and Prognostic Significance of WW Domain Binding Protein 5 Expression in Papillary Thyroid Carcinoma.
Qian Y; Pan Z; Guo Z; Ge X; Zheng G; Cao J; Huang P; Zhu X; Zhu X; Wen Q; Ge M
Biomed Res Int; 2019; 2019():1791065. PubMed ID: 31828091
[TBL] [Abstract][Full Text] [Related]
19. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.
Akslen LA; Varhaug JE
Cancer; 1995 Nov; 76(9):1643-54. PubMed ID: 8635070
[TBL] [Abstract][Full Text] [Related]
20. Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival.
Lo CY; Chan WF; Lam KY; Wan KY
Ann Surg; 2005 Nov; 242(5):708-15. PubMed ID: 16244545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
